Search

Your search keyword '"Qualls, C."' showing total 708 results
Start Over Author "Qualls, C."
708 results on '"Qualls, C."'

51. Primary Care Physicians Utilizing the Echo Model Equally Effective as Subspecialists Treating HCV using Direct-Acting Antivirals-Only Regimens: Results of the Echo Model

Author

Georgie, F., primary, Nafisi, S., additional, Kohli, A., additional, Thornton, K., additional, Reynolds, J., additional, Moore, A., additional, Gish, R., additional, Scott, J., additional, Deming, P., additional, Sedillo, M., additional, Qualls, C., additional, Box, T., additional, Cox, P., additional, Mera, J., additional, Miller, A., additional, Sussman, N., additional, Khaderi, S., additional, Manch, R., additional, and Arora, S., additional

Published
2016
Full Text
View/download PDF

52. Low Sustained Virologic Response (SVR) Rates in Genotype (GT) 2 and 3 Patients with Quantifiable Hepatitis C Virus (HCV) at Week 4 of Treatment with Sofosbuvir (SOF) Containing Regimens

Author

Thornton, K., primary, Deming, P., additional, Sedillo, M., additional, Qualls, C., additional, Box, T., additional, Scott, J., additional, Cox, P., additional, Mera, J., additional, Miller, A., additional, Manch, R., additional, Kohli, A., additional, Gish, R., additional, Moore, A., additional, Sussman, N., additional, Khaderi, S., additional, and Arora, S., additional

Published
2016
Full Text
View/download PDF

54. LP55 : Response guided therapy is not dead: Low Sustained Virologic Response (SVR) rates in patients who have detectable Hepatitis C Virus (HCV) at week 4 of treatment with SOFOSBUVIR (SOF) containing regimens

Author

Thornton, K., primary, Deming, P., additional, Manch, R., additional, Moore, A., additional, Gish, R., additional, Sussman, N., additional, Khaderi, S., additional, Scott, J., additional, Mera, J., additional, Box, T., additional, Qualls, C., additional, Sedillo, M., additional, and Arora, S., additional

Published
2015
Full Text
View/download PDF

55. High sputum total adiponectin is associated with low odds for asthma.

Author

Sood, A, Seagrave, J, Herbert, G, Alam, Y, Chiavaroli, A, Shohreh, R, Montuschi, Paolo, Campen, M, Harmon, M, Qualls, C, Berwick, M, Schuyler, M., Montuschi, Paolo (ORCID:0000-0001-5589-1750), Sood, A, Seagrave, J, Herbert, G, Alam, Y, Chiavaroli, A, Shohreh, R, Montuschi, Paolo, Campen, M, Harmon, M, Qualls, C, Berwick, M, Schuyler, M., and Montuschi, Paolo (ORCID:0000-0001-5589-1750)

Abstract

Objective: Adipose tissue produces adiponectin, an anti-inflammatory protein. High systemic total adiponectin is associated with a low risk for incident asthma but the association with lung adiponectin is not known. Our objective was to evaluate the association between sputum total adiponectin and asthma. Methods: This case-control study included 44 cases with objectively-confirmed asthma and an equal number of body mass index (BMI) and sex-matched controls. Serum and sputum adiponectin were estimated by ELISA and Western Blot technique, respectively. While Fisher's exact test, t-test and Spearman's correlations were used for univariate analyses, Spearman and regression analyses were performed for multivariable analyses. Results: While high-molecular-weight adiponectin was the dominant isoform in serum, medium-molecular-weight isoform was dominant in sputum. Sputum total adiponectin was not correlated with serum adiponectin or BMI. Sputum total adiponectin was lower among asthmatics than controls (p = 0.03), although individual sputum isoforms were not similarly associated. High sputum total adiponectin was associated with lower odds for asthma (OR 0.33, 95% C.I. 0.12, 0.91), even after adjustment for systemic adiposity measures including serum adiponectin. Conclusions: High sputum total adiponectin predicted lower odds for asthma, even after adjustment for serum adiponectin. Although not studied, it is possible that pharmacological modulation of sputum adiponectin may suggest new ways to prevent and/or treat asthma.

Published
2014

64. Differential Mitochondrial Toxicity Screening and Multi-Parametric Data Analysis

Author

Tsiper, Maria V., primary, Sturgis, Jennifer, additional, Avramova, Larisa V., additional, Parakh, Shilpa, additional, Fatig, Raymond, additional, Juan-García, Ana, additional, Li, Nianyu, additional, Rajwa, Bartek, additional, Narayanan, Padma, additional, Qualls, C. W., additional, Robinson, J. Paul, additional, and Davisson, V. Jo, additional

Published
2012
Full Text
View/download PDF

67. Prevention of cesarean section. Does intracervical dinoprostone work?

Author

Gilson, G J, Izquierdo, L A, Chatterjee, M S, Curet, L B, and Qualls, C R

Subjects
reproductive and urinary physiology, Research Article
Abstract

We investigated the effect of preinduction cervical ripening with the intracervical instillation of dinoprostone (prostaglandin E2 gel, 0.5 mg) on the results of labor induced with intravenous oxytocin. We randomly allocated 79 pregnant women to receive either the intracervial application of dinoprostone gel or placebo gel. Compared with control subjects, the group who received dinoprostone had no difference in induction-to-delivery interval or in cesarean section rate. The dinoprostone group had fewer failed inductions, but there was no difference between the two groups in the number who delivered spontaneously within 24 hours. From review of the literature and a meta-analysis, it was likewise revealed that dinoprostone did not favorably affect the cesarean section rate. Contrary to current opinion, intracervical dinoprostone gel does not appreciably lower the cesarean section rate when used at this dose and route before labor is induced.

Published
1993

72. 41

Author

Cherian, Biju, primary, Servilla, Karen, additional, Nguyen, T., additional, Qualls, C., additional, and Tzamaloukas, Antonios, additional

Published
2007
Full Text
View/download PDF

92. Vascular outcome in men with asymptomatic retinal cholesterol emboli. A cohort study.

Author

Bruno A, Jones WL, Austin JK, Carter S, Qualls C, Bruno, A, Jones, W L, Austin, J K, Carter, S, and Qualls, C

Abstract

Objective: To determine whether asymptomatic retinal cholesterol embolism is a risk factor for vascular events.Design: Cohort study with retrospectively selected controls.Setting: A Veterans Affairs medical center.Patients: 70 consecutive patients with asymptomatic retinal cholesterol emboli on dilated ocular examination in an eye clinic and 70 controls without retinal emboli. Controls were matched to patients for sex; age; prevalence of hypertension, diabetes mellitus, and ischemic heart disease; serum cholesterol level; and smoking history.Measurements: Stroke, myocardial infarction, and death.Results: During a mean follow-up of 3.4 years, stroke occurred at an annual rate of 8.5% among patients and 0.8% among controls (adjusted relative risk, 9.9; 95% CI, 2.3 to 43.1; P = 0.002). Nineteen strokes occurred, 17 in patients and 2 in controls; all were nonfatal cerebral infarctions. Twelve of the 17 that occurred in patients were in a carotid artery territory ipsilateral to the qualifying retinal cholesterol embolus and 5 were in another vascular territory. Ocular infarction or hemorrhagic stroke did not occur. Nonfatal myocardial infarction or vascular death occurred at an annual rate of 7.7% among patients and 4.9% among controls (adjusted relative risk, 1.4; 95% CI, 0.7 to 2.9; P = 0.39).Conclusion: Asymptomatic retinal cholesterol embolism is an important risk factor for cerebral infarction independent of commonly recognized vascular risk factors. [ABSTRACT FROM AUTHOR]

Published
1995
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results